vs

Side-by-side financial comparison of CENTERSPACE (CSR) and Health Catalyst, Inc. (HCAT). Click either name above to swap in a different company.

Health Catalyst, Inc. is the larger business by last-quarter revenue ($74.7M vs $66.6M, roughly 1.1× CENTERSPACE). CENTERSPACE runs the higher net margin — -27.7% vs -121.9%, a 94.2% gap on every dollar of revenue. On growth, CENTERSPACE posted the faster year-over-year revenue change (0.3% vs -6.2%). CENTERSPACE produced more free cash flow last quarter ($64.3M vs $9.6M). Over the past eight quarters, CENTERSPACE's revenue compounded faster (1.6% CAGR vs -0.0%).

Centerspace is a real estate investment company specializing in the ownership, operation, and development of high-quality multifamily residential properties. Its core operating markets cover the U.S. Midwest and Mountain West regions, serving diverse renter segments with both affordable and premium housing options, while focusing on tenant experience and long-term asset value growth.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

CSR vs HCAT — Head-to-Head

Bigger by revenue
HCAT
HCAT
1.1× larger
HCAT
$74.7M
$66.6M
CSR
Growing faster (revenue YoY)
CSR
CSR
+6.5% gap
CSR
0.3%
-6.2%
HCAT
Higher net margin
CSR
CSR
94.2% more per $
CSR
-27.7%
-121.9%
HCAT
More free cash flow
CSR
CSR
$54.7M more FCF
CSR
$64.3M
$9.6M
HCAT
Faster 2-yr revenue CAGR
CSR
CSR
Annualised
CSR
1.6%
-0.0%
HCAT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CSR
CSR
HCAT
HCAT
Revenue
$66.6M
$74.7M
Net Profit
$-18.4M
$-91.0M
Gross Margin
96.5%
Operating Margin
-15.9%
-115.3%
Net Margin
-27.7%
-121.9%
Revenue YoY
0.3%
-6.2%
Net Profit YoY
-262.9%
-340.3%
EPS (diluted)
$-1.08
$-1.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CSR
CSR
HCAT
HCAT
Q4 25
$66.6M
$74.7M
Q3 25
$71.4M
$76.3M
Q2 25
$68.5M
$80.7M
Q1 25
$67.1M
$79.4M
Q4 24
$66.4M
$79.6M
Q3 24
$65.0M
$76.4M
Q2 24
$65.0M
$75.9M
Q1 24
$64.5M
$74.7M
Net Profit
CSR
CSR
HCAT
HCAT
Q4 25
$-18.4M
$-91.0M
Q3 25
$53.8M
$-22.2M
Q2 25
$-14.5M
$-41.0M
Q1 25
$-3.7M
$-23.7M
Q4 24
$-5.1M
$-20.7M
Q3 24
$-1.0M
$-14.7M
Q2 24
$-1.3M
$-13.5M
Q1 24
$-3.9M
$-20.6M
Gross Margin
CSR
CSR
HCAT
HCAT
Q4 25
96.5%
Q3 25
96.5%
52.6%
Q2 25
96.5%
Q1 25
96.4%
Q4 24
96.5%
Q3 24
96.6%
47.5%
Q2 24
96.6%
Q1 24
96.4%
Operating Margin
CSR
CSR
HCAT
HCAT
Q4 25
-15.9%
-115.3%
Q3 25
-22.9%
Q2 25
-9.9%
-46.0%
Q1 25
7.1%
-25.4%
Q4 24
4.3%
-22.0%
Q3 24
9.8%
-17.9%
Q2 24
11.1%
-20.8%
Q1 24
6.3%
-30.5%
Net Margin
CSR
CSR
HCAT
HCAT
Q4 25
-27.7%
-121.9%
Q3 25
75.3%
-29.1%
Q2 25
-21.2%
-50.8%
Q1 25
-5.6%
-29.9%
Q4 24
-7.6%
-26.0%
Q3 24
-1.6%
-19.3%
Q2 24
-2.0%
-17.8%
Q1 24
-6.1%
-27.6%
EPS (diluted)
CSR
CSR
HCAT
HCAT
Q4 25
$-1.08
$-1.29
Q3 25
$3.19
$-0.32
Q2 25
$-0.87
$-0.59
Q1 25
$-0.22
$-0.35
Q4 24
$-0.31
$-0.33
Q3 24
$-0.40
$-0.24
Q2 24
$-0.19
$-0.23
Q1 24
$-0.37
$-0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CSR
CSR
HCAT
HCAT
Cash + ST InvestmentsLiquidity on hand
$12.8M
$95.7M
Total DebtLower is stronger
$1.0B
$153.3M
Stockholders' EquityBook value
$719.2M
$245.8M
Total Assets
$1.9B
$502.6M
Debt / EquityLower = less leverage
1.42×
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CSR
CSR
HCAT
HCAT
Q4 25
$12.8M
$95.7M
Q3 25
$12.9M
$91.5M
Q2 25
$12.4M
$97.3M
Q1 25
$11.9M
$342.0M
Q4 24
$12.0M
$392.0M
Q3 24
$14.5M
$387.3M
Q2 24
$14.3M
$308.3M
Q1 24
$12.7M
$327.8M
Total Debt
CSR
CSR
HCAT
HCAT
Q4 25
$1.0B
$153.3M
Q3 25
$1.1B
$153.1M
Q2 25
$1.1B
$153.0M
Q1 25
$955.5M
$382.9M
Q4 24
$955.4M
$382.4M
Q3 24
$921.3M
$345.0M
Q2 24
$931.7M
Q1 24
$929.1M
Stockholders' Equity
CSR
CSR
HCAT
HCAT
Q4 25
$719.2M
$245.8M
Q3 25
$748.6M
$331.9M
Q2 25
$710.1M
$347.5M
Q1 25
$636.8M
$376.8M
Q4 24
$752.0M
$365.2M
Q3 24
$672.5M
$355.0M
Q2 24
$680.7M
$357.0M
Q1 24
$688.1M
$357.2M
Total Assets
CSR
CSR
HCAT
HCAT
Q4 25
$1.9B
$502.6M
Q3 25
$2.1B
$587.1M
Q2 25
$2.0B
$616.2M
Q1 25
$1.9B
$891.5M
Q4 24
$1.9B
$858.9M
Q3 24
$1.9B
$813.0M
Q2 24
$1.9B
$691.7M
Q1 24
$1.9B
$695.1M
Debt / Equity
CSR
CSR
HCAT
HCAT
Q4 25
1.42×
0.62×
Q3 25
1.53×
0.46×
Q2 25
1.57×
0.44×
Q1 25
1.50×
1.02×
Q4 24
1.27×
1.05×
Q3 24
1.37×
0.97×
Q2 24
1.37×
Q1 24
1.35×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CSR
CSR
HCAT
HCAT
Operating Cash FlowLast quarter
$98.5M
$9.9M
Free Cash FlowOCF − Capex
$64.3M
$9.6M
FCF MarginFCF / Revenue
96.5%
12.9%
Capex IntensityCapex / Revenue
51.3%
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$125.9M
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CSR
CSR
HCAT
HCAT
Q4 25
$98.5M
$9.9M
Q3 25
$35.1M
$-464.0K
Q2 25
$25.3M
$-9.0M
Q1 25
$25.4M
$280.0K
Q4 24
$98.2M
$-3.5M
Q3 24
$32.3M
$6.2M
Q2 24
$22.9M
$1.6M
Q1 24
$24.4M
$10.3M
Free Cash Flow
CSR
CSR
HCAT
HCAT
Q4 25
$64.3M
$9.6M
Q3 25
$25.7M
$-719.0K
Q2 25
$15.5M
$-9.2M
Q1 25
$20.4M
$-390.0K
Q4 24
$41.6M
$-3.9M
Q3 24
$20.5M
$5.5M
Q2 24
$9.1M
$1.3M
Q1 24
$2.6M
$10.1M
FCF Margin
CSR
CSR
HCAT
HCAT
Q4 25
96.5%
12.9%
Q3 25
36.0%
-0.9%
Q2 25
22.7%
-11.4%
Q1 25
30.4%
-0.5%
Q4 24
62.6%
-4.9%
Q3 24
31.5%
7.2%
Q2 24
14.0%
1.7%
Q1 24
4.0%
13.5%
Capex Intensity
CSR
CSR
HCAT
HCAT
Q4 25
51.3%
0.4%
Q3 25
13.1%
0.3%
Q2 25
14.2%
0.3%
Q1 25
7.5%
0.8%
Q4 24
85.3%
0.5%
Q3 24
18.2%
0.9%
Q2 24
21.2%
0.4%
Q1 24
33.8%
0.3%
Cash Conversion
CSR
CSR
HCAT
HCAT
Q4 25
Q3 25
0.65×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CSR
CSR

Multi Family Residential$57.3M86%
Other$8.1M12%
Other Property Revenue$1.2M2%

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

Related Comparisons